The contribution of inhibins and activins to malignant prostate disease

Abstract

The normal human prostate expresses inhibin and activin subunits. In prostate cancer, the inhibin α subunit gene is down regulated and this is associated with loss of heterozygosity (LOH) at the gene locus and methylation of the promoter. These data support the hypothesis that the inhibin α subunit is tumor suppressive in the prostate. The pluripotent effects of activins and the similarities to transforming growth factor β (TFGβ) suggest a role for activins in progression to malignancy, whereby, the normal growth inhibitory action of activin A observed on benign cells is lost with the acquisition of activin resistance in prostate cancer cells. The mechanisms of rendering tumor cells resistant to activin A may include: alteration in activin binding protein (follistatin) synthesis and/or dimerisation with activin β C to form novel activin dimers. The contribution of the activin signalling cascade to malignancy requires further evaluation to identify the synergies and differences to other members of the TGFβ superfamily.